NCT05199714View on ClinicalTrials.gov

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

March 25, 2023

Study Completion Date

March 25, 2023

Conditions
Type 1 Diabetes
Interventions
DRUG

Fiasp

Fiasp Insulin delivered in a basal-bolus manner.

DEVICE

Artificial Pancreas

Medtronic insulin pump, Dexcom G6 continuous glucose sensor, tablet running the Artificial Pancreas Algorithm.

DRUG

Pramlintide

Pramlintide delivered in a basal-bolus manner.

DRUG

Aspart

Aspart insulin delivered in a basal-bolus manner.

Trial Locations (1)

H4A 3T2

Research Institute of the McGill University Health Center, Montreal

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER